Parkinson Platform Noord Nederland

In 2018, several initiatives that have aimed to slow progression or prevent development of movement disorders have provided encouraging results. In mouse models of Parkinson's disease, drugs that activate glucagon-like peptide 1 (GLP-1) receptors have been shown to target neuroinflammation, reduce microglial activation following exposure to aggregated α-synuclein, and prevent microglial-mediated conversion of astrocytes to a neurotoxic phenotype.1 Mild improvements of motor scores in patients with Parkinson's disease who were treated with the GLP-1 receptor agonist exenatide compared with placebo2 need to be confirmed in other studies (NCT02953665 for liraglutide, NCT03659682 for semaglutide).